GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » ROC (Joel Greenblatt) %

Endo International (Endo International) ROC (Joel Greenblatt) % : -1,142.16% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Endo International ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Endo International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1,142.16%.

The historical rank and industry rank for Endo International's ROC (Joel Greenblatt) % or its related term are showing as below:

ENDPQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -515.52   Med: -79.92   Max: 96.27
Current: -276.62

During the past 13 years, Endo International's highest ROC (Joel Greenblatt) % was 96.27%. The lowest was -515.52%. And the median was -79.92%.

ENDPQ's ROC (Joel Greenblatt) % is ranked worse than
89.11% of 1065 companies
in the Drug Manufacturers industry
Industry Median: 8.06 vs ENDPQ: -276.62

Endo International's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Endo International ROC (Joel Greenblatt) % Historical Data

The historical data trend for Endo International's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International ROC (Joel Greenblatt) % Chart

Endo International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.73 96.27 3.40 -402.76 -285.88

Endo International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109.33 1.48 15.33 -7.65 -1,142.16

Competitive Comparison of Endo International's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Endo International's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endo International's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo International's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Endo International's ROC (Joel Greenblatt) % falls into.



Endo International ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(387.485 + 273.831 + 261.811) - (563.734 + 0 + -1.1368683772162E-13)
=359.393

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(386.919 + 246.017 + 249.865) - (537.838 + 0 + 0)
=344.963

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Endo International for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9648.064/( ( (485.812 + max(359.393, 0)) + (499.273 + max(344.963, 0)) )/ 2 )
=-9648.064/( ( 845.205 + 844.236 )/ 2 )
=-9648.064/844.7205
=-1,142.16 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endo International  (OTCPK:ENDPQ) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Endo International ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Endo International's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Endo International (Endo International) Business Description

Traded in Other Exchanges
Address
Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.
Executives
James Patrick Tursi officer: Executive VP, Global R&D 106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti officer: VP, Controller and CAO C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague director
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol officer: EVP, Head of Global R&D C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith director 3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley officer: EVP, Chief Financial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio director 19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle officer: SVP, Interim Controller C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel director LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico officer: EVP & Chief Commercial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella officer: EVP, Intl Pharmaceuticals C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol officer: VP, Controller & CAO 927 GRANDVIEW DRIVE, EXTON PA 19341

Endo International (Endo International) Headlines

From GuruFocus